Medical News

RSS

Trovagene completes PCR assay development for detection of K-RAS mutations

Trovagene, Inc., a developer of trans-renal molecular diagnostics, announced today that the Company has successfully completed the analytical development of digital PCR assays for the detection of the most prevalent K-RAS mutations, which are, according to recent estimates, observed in more than 90% of pancreatic cancers, and in 23% of all solid tumors.

30 Apr 2012

Airborne drones could provide innovative method of delivering food, medicines

In a Foreign Policy opinion piece, former U.S. Ambassador Jack Chow, who served as a special representative for HIV/AIDS under former Secretary of State Colin Powell and currently is a professor at Carnegie Mellon's Heinz College of Public Policy, examines the challenges of delivering humanitarian aid and how "[t]he technological versatility of airborne drones, the flying robots that are already transforming warfare, ... has the potential to revolutionize how humanitarian aid is delivered worldwide."

30 Apr 2012

Feds approve Wisconsin Medicaid cuts

Meanwhile, Kansas applies for waiver to shift Medicaid beneficiaries into managed care plans and Medicaid costs in Kentucky weigh on one insurer.

30 Apr 2012

Kadimastem, Merck Serono enter agreement for MS drug-screening platform

Kadimastem, an Israeli Biotechnology company that develops human pluripotent stem cell-related products, today announced the signing of a five year framework agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

30 Apr 2012

GE Capital provides $7.5M in senior secured credit facilities to PharmAthene

GE Capital, Healthcare Financial Services announced today that it was sole lender and administrative agent on $7.5 million in senior secured credit facilities for PharmAthene, consisting of a $2.5 million term loan and a $5 million revolving line of credit.

30 Apr 2012

Rexahn obtains additional patent coverage for anti-cancer candidate RX-1792 in Japan

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued to the Company patent No. 4,934,432, entitled "Quinazoline Derivatives and Therapeutic Use Thereof."

30 Apr 2012

JCO publishes Syndax erlotinib-entinostat Phase 2 study for advanced non-small cell lung cancer

Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO).

30 Apr 2012

Covidien acquires PolyTouch Medical

PolyTouch Medical Ltd., a leading developer of hernia mesh placement technologies, was acquired by Covidien, a leading global provider of healthcare products that is traded on the New York Stock Exchange at a current market value of $26 billion.

30 Apr 2012

Astounding lack of public awareness about lung cancer

An astounding lack of public awareness about lung cancer has been revealed in a Cancer Research UK study, published today.

30 Apr 2012

First Edition: April 30, 2012

In today's headlines, a variety of health policy headlines ranging from reports about state-level health law implementation progress to marketplace news.

30 Apr 2012

Potential hazards of performing MRI in patients with cardiac pacemaker

Great care should be taken when performing magnetic resonance imaging (MRI) in patients with a cardiac pacemaker. Henning Bovenschulte and his co-authors review recent findings in the latest issue of Deutsches Ärzteblatt International.

30 Apr 2012

Conjoined twins bounce back after separation surgery

Angelica Sabuco runs to kiss her sister Angelina on the cheek, and then runs away giggling. Angelina squeals and starts chasing her twin around the grass, determined to get her kiss in, too. It's hard to believe that a short while ago, these same two girls were struggling to even walk, and facing an uncertain future.

30 Apr 2012

Bacteria in belly buttons, armpits, and chronic wounds

Minutes after you were born, bacteria moved in. Since then, their populations have exploded, diversified and spread—on your skin and eyes and in your mouth and gut, not to mention other places. These bacterial cells now far outnumber your own cells.

30 Apr 2012

Teva, Mylan settle patent infringement litigation for Nuvigil

Teva Pharmaceutical Industries Ltd., one of the world's largest producers of pharmaceuticals, announces that it has settled patent infringement litigation regarding U.S. Patent Number 7,132,570 (the "'570 patent") with respect to Mylan Inc.'s ANDA for Teva's wakefulness product NUVIGIL (armodafinil) tablets.

30 Apr 2012

BTG launches Voraxaze for treatment of toxic plasma methotrexate

BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.

30 Apr 2012

Enrollment complete in Zalicus Synavive Phase 2b clinical trial for rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced it has completed enrollment with 292 patients enrolled in the SYNERGY trial, a Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).

30 Apr 2012

New class of drugs hold promise against aggressive forms of pancreatic cancer

Cancer Research UK-funded scientists have shown how a promising new class of drugs might be used to treat aggressive forms of pancreatic cancer, according to a study published in Nature.

30 Apr 2012

Watson first quarter net income increases 87% to $208.8 million

Watson Pharmaceuticals, Inc. today reported net income for the first quarter 2012 increased 87 percent to $208.8 million or $1.64 per diluted share on a non-GAAP basis, compared to $111.9 million or $0.89 per diluted share in the first quarter 2011.

30 Apr 2012

Tolero granted exclusive global rights to commercialize MannKind's novel BTK compounds

Tolero Pharmaceuticals and MannKind Corporation today announced a license agreement granting Tolero exclusive worldwide rights to develop and commercialize compounds from MannKind's novel BTK (Bruton's tyrosine kinase) program, which are currently being developed for the treatment of hematological malignancies and inflammatory diseases.

30 Apr 2012